Compare FTEK & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTEK | QTTB |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 44.3M |
| IPO Year | 1997 | 2018 |
| Metric | FTEK | QTTB |
|---|---|---|
| Price | $1.26 | $5.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 215.5K | 201.4K |
| Earning Date | 03-03-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | $30,467,000.00 | ★ $53,737,000.00 |
| Revenue This Year | $24.81 | N/A |
| Revenue Next Year | $16.33 | N/A |
| P/E Ratio | ★ N/A | $2.37 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $1.38 |
| 52 Week High | $3.64 | $7.80 |
| Indicator | FTEK | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 59.59 |
| Support Level | N/A | $1.64 |
| Resistance Level | $1.51 | $6.37 |
| Average True Range (ATR) | 0.10 | 0.68 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 19.74 | 47.52 |
Fuel Tech Inc is an technology provider of boiler optimization, efficiency improvement, and air pollution reduction to utility and industrial customers. The company operates in two segments, Air Pollution Control and Fuel Chem. The Air Pollution Control technology segment includes technologies to reduce NOx emissions in flue gas from boilers, incinerators, furnaces and other stationary combustion sources. The Fuel Chem technology segment uses chemical processes in combination with Computational Fluid Dynamics and Chemical Kinetics Modeling boiler modeling for the control of slagging, fouling, corrosion, opacity and other sulfur trioxide-related issues in furnaces and boilers through the addition of chemicals into the furnace using TIFI Targeted In-Furnace Injection technology.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.